Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18,331 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Optimal management of lenvatinib therapy for patients with unresectable hepatocellular carcinoma by balancing the therapeutic effect with the relative dose intensity.
Tokunaga T, Tateyama M, Tanaka K, Narahara S, Inada H, Kurano S, Hayashi S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: tanaka m, tanaka k, tanaka y. Hepatol Res. 2022 Jan;52(1):105-119. doi: 10.1111/hepr.13720. Epub 2021 Oct 22. Hepatol Res. 2022. PMID: 34626450
Modified albumin-bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients.
Tokunaga T, Tanaka M, Tanaka K, Narahara S, Kawasaki T, Yoshimaru Y, Nagaoka K, Watanabe T, Tateyama M, Naoe H, Sasaki Y, Tanaka Y. Tokunaga T, et al. Among authors: tanaka m, tanaka k, tanaka y. Int J Clin Oncol. 2021 May;26(5):922-932. doi: 10.1007/s10147-020-01835-2. Epub 2021 Mar 17. Int J Clin Oncol. 2021. PMID: 33730200
Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma.
Narahara S, Watanabe T, Nagaoka K, Fujimoto N, Furuta Y, Tanaka K, Tokunaga T, Kawasaki T, Yoshimaru Y, Setoyama H, Oniki K, Saruwatari J, Tateyama M, Naoe H, Tanaka M, Tanaka Y, Sasaki Y. Narahara S, et al. Among authors: tanaka m, tanaka k, tanaka y. Hepatol Commun. 2022 May;6(5):1198-1212. doi: 10.1002/hep4.1872. Epub 2021 Nov 27. Hepatol Commun. 2022. PMID: 34837478 Free PMC article.
Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
Tokunaga T, Tateyama M, Kondo Y, Miuma S, Miyase S, Tanaka K, Narahara S, Inada H, Kurano S, Yoshimaru Y, Nagaoka K, Watanabe T, Setoyama H, Fukubayashi K, Tanaka M, Tanaka Y. Tokunaga T, et al. Among authors: tanaka m, tanaka k, tanaka y. Cancers (Basel). 2023 Mar 2;15(5):1568. doi: 10.3390/cancers15051568. Cancers (Basel). 2023. PMID: 36900359 Free PMC article.
Randomized phase I/II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.
Yoshimaru Y, Nagaoka K, Tanaka K, Narahara S, Inada H, Kurano S, Tokunaga T, Iio E, Watanabe T, Setoyama H, Tateyama M, Yoshida K, Tsunoda T, Nakamura Y, Tanaka M, Sasaki Y, Tanaka Y. Yoshimaru Y, et al. Among authors: tanaka m, tanaka k, tanaka y. Hepatol Res. 2024 May;54(5):451-464. doi: 10.1111/hepr.13995. Epub 2023 Dec 27. Hepatol Res. 2024. PMID: 38018304
18,331 results
You have reached the last available page of results. Please see the User Guide for more information.